Please select the option that best describes you:

Are you checking for any specific mutations in NSCLC that suggest resistance to checkpoint inhibitors?   

Are there any biomarkers that would affect your decision for first line PD-1 therapy (including but not limited to STK11)? 



Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at PINNACLE ONCOLOGY AND HEMATOLOGY
Dr. Dowlati, thank you for the detailed response.&...
Sign in or Register to read more